trading opportunity, page-8

Assuming a very good Ph 3 outcome they may consider trying to take a mCRC drug to market in their own right, at a cost of around $50 million - which would need a capital raising. And then, extra cash would be needed to progress other oncology prospects, plus VAST. When I asked ACL several months back, it was 'suggested' that there was no appetite to revisit a NASDQ listing/raising. Perhaps that's changed? There are far more knowledgable people on HC than me, but I'd think if (repeat "if") the mCRC trial is a winner, may be best if they did a fairly quick licensing deal for mCRC; and then a smaller capital raising to advance other products